Kamada Ltd.
A biopharmaceutical company specializing in plasma-derived protein therapeutics.
KMDA | TA
Overview
Corporate Details
- ISIN(s):
- IL0010941198
- LEI:
- Country:
- Israel
- Address:
- 2 Holzman St, Science Park, 7670402 Rehovot
- Website:
- https://www.kamada.com
- Sector:
- Manufacturing
Description
Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-04-27 16:02 |
KamadaandKedrionBiopharmaAnnounceGlobalCollaborationfortheDevelopment,Manufactu…
|
English | 38.0 KB | ||
| 2020-03-25 20:07 |
Results of the Extraordinary General Meeting of Shareholders held on March 25, …
|
English | 67.8 KB | ||
| 2020-03-25 20:07 |
Results of the Extraordinary General Meeting of Shareholders held on March 25, …
|
English | 37.9 KB | ||
| 2020-03-16 14:59 |
amendment No.1 to the annual report on Form 20-F for the fiscal year ended Dece…
|
English | 147.6 KB | ||
| 2020-03-16 14:59 |
amendment No.1 to the annual report on Form 20-F for the fiscal year ended Dece…
|
English | 37.9 KB | ||
| 2020-03-11 13:59 |
Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobu…
|
English | 176.8 KB | ||
| 2020-03-11 13:59 |
Kamada Provides Update on Progress Related to its Proprietary Hyper-Immunoglobu…
|
English | 38.1 KB | ||
| 2020-02-26 17:37 |
FORM 6-K, It has filed its Annual Report for the Year Ended December 31, 2019
|
English | 132.3 KB | ||
| 2020-02-26 17:37 |
FORM 6-K, It has filed its Annual Report for the Year Ended December 31, 2019
|
English | 37.8 KB | ||
| 2020-02-26 17:33 |
FORM 20-F
|
English | 5.4 MB | ||
| 2020-02-26 17:33 |
FORM 20-F
|
English | 38.0 KB | ||
| 2020-02-13 20:22 |
6K: Kamada notice and Proxy Statement for the Extraordinary General Meeting of …
|
English | 347.3 KB | ||
| 2020-02-13 20:22 |
6K: Kamada notice and Proxy Statement for the Extraordinary General Meeting of …
|
English | 37.9 KB | ||
| 2020-02-12 15:00 |
Financial Results for Fourth Quarter and Fiscal Year 2019
|
English | 364.0 KB | ||
| 2020-02-12 15:00 |
Financial Results for Fourth Quarter and Fiscal Year 2019
|
English | 37.9 KB |
Automate Your Workflow. Get a real-time feed of all Kamada Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kamada Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kamada Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
